Impax Global Equity Opportunities Fund A USD AccRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | - | - | 9.0 | |
+/-Cat | - | - | - | - | -2.3 | |
+/-B’mrk | - | - | - | - | -7.9 | |
Category: Global Large-Cap Growth Equity | ||||||
Category Benchmark: Morningstar Gbl Growth TME ... |
Key Stats | ||
NAV 20/11/2024 | USD 1.17 | |
Day Change | 0.02% | |
Morningstar Category™ | Global Large-Cap Growth Equity | |
ISIN | IE00BJKWZ924 | |
Fund Size (Mil) 20/11/2024 | GBP 1176.35 | |
Share Class Size (Mil) 20/11/2024 | USD 89.31 | |
Max Initial Charge | - | |
Ongoing Charge 31/07/2024 | 1.09% |
Investment Objective: Impax Global Equity Opportunities Fund A USD Acc |
The Fund’s investment objective is to generate long term capital growth through an actively managed portfolio of equities from issuers across global equity markets. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
David Winborne 01/01/2018 | ||
Kirsteen Morrison 01/01/2014 | ||
Inception Date 16/11/2023 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
Not Benchmarked | Morningstar Gbl Growth TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Impax Global Equity Opportunities Fund A USD Acc | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Microsoft Corp | Technology | 4.20 |
Mastercard Inc Class A | Financial Services | 3.91 |
Alcon Inc | Healthcare | 3.90 |
Boston Scientific Corp | Healthcare | 3.84 |
Linde PLC | Basic Materials | 3.72 |
Increase Decrease New since last portfolio | ||
Impax Global Equity Opportunities Fund A USD Acc |